Genetic Insights into Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a complex, progressive eye disease that predominantly affects older individuals and is a leading cause of vision loss globally.

Life Sciences Review | Friday, January 24, 2025

Age-related macular degeneration (AMD) is a complex, progressive eye disease that predominantly affects older individuals and is a leading cause of vision loss globally. Genetic testing for AMD has emerged as a valuable tool in understanding the disease's etiology, assessing individual risk, and exploring personalized treatment options. This article delves into the science behind AMD genetic testing, its current applications, and its potential implications for future ophthalmic care.

AMD primarily affects the macula, the central portion of the retina responsible for sharp and detailed vision. It manifests in two main forms: dry (atrophic) and wet (neovascular). The dry form is characterized by the accumulation of drusen, which are yellow deposits beneath the retina, leading to progressive thinning and atrophy of retinal tissue. The wet form, on the other hand, involves abnormal blood vessel growth beneath the retina, often resulting in sudden and severe vision loss.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Genetic predisposition plays a crucial role in the development of AMD. Studies have identified numerous genetic variants associated with the disease, with the complement system being a key area of focus. Variants in genes such as CFH (complement factor H), CFI (complement factor I), C3, and C2/CFB have been implicated in altering the regulation of the complement cascade, leading to chronic inflammation and tissue damage in the retina. Other genetic factors include polymorphisms in the ARMS2/HTRA1 region, which are strongly associated with the wet form of AMD.

Genetic testing for AMD involves analyzing specific gene variants to determine an individual's susceptibility to the disease. Such testing can identify individuals at higher risk, facilitate early interventions, and inform lifestyle modifications to mitigate risk. While genetic testing does not diagnose AMD, it provides insight into a person’s likelihood of developing the disease based on their genetic makeup.

Modern genetic testing for AMD utilizes advanced techniques such as polymerase chain reaction (PCR), single nucleotide polymorphism (SNP) genotyping, and next-generation sequencing (NGS). These methodologies enable the detection of specific mutations and polymorphisms in genes associated with AMD. Commercially available genetic tests often target well-established AMD-related variants, including those in the CFH and ARMS2/HTRA1 genes.

The application of genetic testing in AMD extends beyond risk assessment. It aids in differentiating AMD from other retinal disorders with similar presentations. Moreover, understanding a patient’s genetic profile can guide clinical decision-making, particularly in tailoring therapeutic interventions. For instance, individuals with certain genetic variants may respond differently to specific treatments, such as anti-vascular endothelial growth factor (anti-VEGF) therapy, which is the cornerstone of managing wet AMD.

Genetic testing also has implications for family counseling. Given the hereditary nature of AMD, identifying high-risk individuals within families can prompt early monitoring and preventive strategies. Lifestyle changes, such as smoking cessation, a diet rich in antioxidants and omega-3 fatty acids, and regular exercise, can be emphasized for at-risk individuals to slow disease progression.

Despite its potential benefits, AMD genetic testing poses several challenges and raises ethical concerns. One significant issue is the interpretation of test results. While certain genetic variants are strongly associated with AMD, the disease is multifactorial, with environmental factors such as smoking and diet also playing a critical role. Thus, a positive genetic test result does not guarantee disease onset, nor does a negative result exclude the possibility of developing AMD.

Another challenge lies in the psychological impact of genetic testing. Learning about an increased genetic risk for AMD can cause anxiety and stress, particularly when no definitive preventive measures or cures are available. Counseling before and after testing is essential to help individuals understand the implications of their results and cope with the associated emotional burden.

The cost of genetic testing is another barrier to its widespread adoption. While the prices of genetic tests have decreased over time, they may still be prohibitive for some individuals. Additionally, concerns about genetic privacy and the potential misuse of genetic information by employers or insurers further complicate the landscape of genetic testing. The field of AMD genetic testing is rapidly evolving, with ongoing research focused on identifying new genetic markers and understanding their functional roles in disease pathogenesis. Advances in genomics and bioinformatics are expected to enhance the accuracy and comprehensiveness of genetic testing, paving the way for more personalized approaches to AMD management. Genetic testing for AMD is a powerful tool that offers valuable insights into the genetic underpinnings of this prevalent eye disease. By identifying individuals at risk, informing personalized treatment strategies, and guiding preventive measures, genetic testing has the potential to transform the landscape of AMD care. However, challenges such as result interpretation, psychological impact, cost, and ethical considerations must be addressed to maximize its benefits.

As research continues to uncover new genetic markers and therapeutic approaches, the integration of genetic testing into routine ophthalmic practice is likely to expand. With advancements in genomics and precision medicine, the future holds great promise for improving outcomes for individuals with AMD and reducing the burden of this vision-threatening condition on society

More in News

Pharmaceutical Compliance in a Serialized Supply Chain

Pharmaceutical compliance has moved beyond recordkeeping into the daily movement of product, data and accountability across the supply chain. For manufacturers, wholesale distributors and third-party logistics providers, compliance now depends on whether each package can be identified, verified, traced and reported without forcing teams to reconcile disconnected systems. The pressure is not only regulatory. Counterfeit risk, expired product control, trading partner accuracy and audit readiness all sit inside the same business workflow. A strong compliance platform must bring those demands together without turning compliance into a parallel process that slows commercial activity or leaves leaders dependent on fragmented reports. The most reliable solutions are built around traceability at the transaction level. Serialization cannot be treated as a late-stage attachment to inventory management because the value of a serial number depends on how consistently it travels through purchasing, receiving, sales, returns, financial records and partner exchange. When serialization lives outside the system that manages the business, companies often inherit duplicate entries, timing gaps and inconsistent product data. Those weaknesses become expensive when regulators require proof, customers request verification or leadership needs a clean view of inventory exposure. A better system keeps compliance evidence close to the events that create it, allowing teams to act from the same source of truth rather than comparing data after problems appear. Executives should also look closely at how a platform handles reporting and exception management. Pharma teams need systems that can capture required data, generate reports and support Drug Supply Chain Security Act obligations without relying on manual workarounds. The right solution should reduce dependence on extra staffing for routine tasks, give teams timely visibility into product status and help prevent expired or suspect products from moving forward. Compliance technology should not simply store information. It should make the right information available when a trading partner, regulator or internal leader needs it. That level of discipline becomes especially important for companies operating across multiple states, serving many customers or managing products whose lifecycle data must remain accurate from receipt to distribution. Data protection has become equally central because cloud-based compliance systems hold commercially sensitive information about product movement, customers, orders and financial activity. Encryption, network security, threat detection and compliance controls are no longer supporting features. They are part of the decision. Executives need confidence that the platform protects proprietary data while still enabling authorized users to work across sites, functions and partners. Scalability also matters because pharmaceutical companies rarely remain static. License expansion, new partner relationships, added states, higher transaction volume and broader service lines can quickly expose whether a system was designed for growth or merely configured for a current process. “ For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. “ This is where RxERP stands out as the premier choice for pharmaceutical organizations that need compliance embedded into core business execution rather than added around it. Its platform combines ERP functionality with automated serialization, traceability, reporting, inventory, finance, CRM and business intelligence for manufacturers, distributors and third-party logistics providers. The transcript points to a wholesaler and 3PL that replaced fragmented systems with one integrated platform, improving automation, reporting, data management and DSCSA compliance while achieving measurable financial and revenue gains. For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Specials

Genetic Insights into Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a complex, progressive eye disease that predominantly affects older individuals and is a leading cause of vision loss globally.